Professor Keith Channon, Co-founder & Chief Medical Officer, Caristo Diagnostics, shares results from the ORFAN study unveiled at American Heart Association (AHA)’s Late-Breaking Science Session with leading healthcare media outlet, Cardiovascular Business.
Watch his interview
Cari-Heart® Technology was featured as one of the innovations offering renewed hope to people with heart and circulatory diseases, on a special programme for #WorldHeartDay in 2023
Professor Charalambos Antoniades discusses the scientific discovery underpinning CaRi-Heart technology.
Watch the video
Coronary Artery Disease (CAD) is the world’s biggest killer, but often goes unnoticed until it is too late. For decades, cardiologists have known that inflammation is the key process that drives the development of CAD and plaque rupture; but it is not detectable with current routine diagnostic tests.
Learn more
Caristo has developed state-of-the-art image analysis technology, that can detect and quantify the invisible signatures of inflammation in routine CT heart scans. This non-invasive technique is widely available and cost-effective.
Learn more
Combining our proprietary measurements of coronary artery inflammation and plaque characteristics, with other clinical risk factors, we can accurately predict an individual’s risk of heart attack to guide therapy.
The prognostic value of our technology has been validated in thousands of patients in several cohorts such as CRISP-CT or SCOT-HEART
See how Caristo can help you.
